Cargando…

Mitochondrial apoptosis and BH3 mimetics

The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dai, Haiming, Meng, X. Wei, Kaufmann, Scott H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	F1000Research 2016
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5133681/ https://www.ncbi.nlm.nih.gov/pubmed/27990281 http://dx.doi.org/10.12688/f1000research.9629.1

Ejemplares similares

Transient binding of an activator BH3 domain to the Bak BH3-binding groove initiates Bak oligomerization
por: Dai, Haiming, et al.
Publicado: (2011)

BH3 mimetics efficiently induce apoptosis in mouse basophils and mast cells
por: Reinhart, Ramona, et al.
Publicado: (2018)

DRP-1 is required for BH3 mimetic-mediated mitochondrial fragmentation and apoptosis
por: Milani, Mateus, et al.
Publicado: (2017)

BH3 Mimetics in Hematologic Malignancies
por: Klener, Pavel, et al.
Publicado: (2021)

Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies
por: Jullien, Maxime, et al.
Publicado: (2020)

Selective BH3 mimetics synergize with BET inhibition to induce mitochondrial apoptosis in rhabdomyosarcoma cells
por: Erdogdu, Ufuk, et al.
Publicado: (2021)

The application of BH3 mimetics in myeloid leukemias
por: Parry, Narissa, et al.
Publicado: (2021)

BH3-mimetics: recent developments in cancer therapy
por: Townsend, Paul A., et al.
Publicado: (2021)

BH3 mimetics induce apoptosis independent of DRP-1 in melanoma
por: Mukherjee, Nabanita, et al.
Publicado: (2018)

DRP-1 functions independently of mitochondrial structural perturbations to facilitate BH3 mimetic-mediated apoptosis
por: Milani, Mateus, et al.
Publicado: (2019)

Characterization of an alternative BAK-binding site for BH3 peptides
por: Ye, Kaiqin, et al.
Publicado: (2020)

Bak Conformational Changes Induced by Ligand Binding: Insight into BH3 Domain Binding and Bak Homo-Oligomerization
por: Pang, Yuan-Ping, et al.
Publicado: (2012)

The Role of BH3-Mimetic Drugs in the Treatment of Pediatric Hepatoblastoma
por: Lieber, Justus, et al.
Publicado: (2015)

Adapted to Survive: Targeting Cancer Cells with BH3 Mimetics
por: Montero, Joan, et al.
Publicado: (2022)

On BH3 Mimetics and Ca(2+) Signaling
por: Ferdek, Pawel E., et al.
Publicado: (2017)

BET-inhibitors as sensitizers for BH3-mimetics
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

BH3 Mimetics for the Treatment of Prostate Cancer
por: Wolf, Philipp
Publicado: (2017)

Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study
por: Rohner, Lionel, et al.
Publicado: (2020)

Sensitivity of canine hematological cancers to BH3 mimetics
por: Jegatheeson, Selvi, et al.
Publicado: (2022)

Hypericin, a potential new BH3 mimetic
por: Doroshenko, Anastasia, et al.
Publicado: (2022)

The BH3 mimetic (±) gossypol induces ROS-independent apoptosis and mitochondrial dysfunction in human A375 melanoma cells in vitro
por: Haasler, Lisa, et al.
Publicado: (2021)

Defining the susceptibility of colorectal cancers to BH3-mimetic compounds
por: Luo, Ming-Jie, et al.
Publicado: (2020)

The BH3 Mimetic Obatoclax Accumulates in Lysosomes and Causes Their Alkalinization
por: Stamelos, Vasileios A., et al.
Publicado: (2016)

Overcoming EMT-driven therapeutic resistance by BH3 mimetics
por: Keitel, Ulrike, et al.
Publicado: (2014)

Computational modeling of DLBCL predicts response to BH3-mimetics
por: Cloete, Ielyaas, et al.
Publicado: (2023)

BH3 Mimetics for the Treatment of B-Cell Malignancies—Insights and Lessons from the Clinic
por: Lin, Victor S., et al.
Publicado: (2020)

BCL-2 family deregulation in colorectal cancer: potential for BH3 mimetics in therapy
por: Ramesh, Prashanthi, et al.
Publicado: (2020)

BH3 profiling and a toolkit of BH3-mimetic drugs predict anti-apoptotic dependence of cancer cells
por: Butterworth, Michael, et al.
Publicado: (2016)

Dynamic BH3 profiling identifies active BH3 mimetic combinations in non-small cell lung cancer
por: Potter, Danielle S., et al.
Publicado: (2021)

The Growing Role of the BH3 Mimetic Drug Venetoclax in the Therapy of Acute Myeloid Leukemia
por: Pelosi, Elvira, et al.
Publicado: (2022)

Dynamic BH3 profiling method for rapid identification of active therapy in BH3 mimetics resistant xenograft mouse models
por: Olesinski, Elyse A., et al.
Publicado: (2021)

Inhibition of the Anti-Apoptotic Bcl-2 Family by BH3 Mimetics Sensitize the Mitochondrial Permeability Transition Pore Through Bax and Bak
por: Patel, Pooja, et al.
Publicado: (2021)

The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular cells
por: Cheng, P, et al.
Publicado: (2013)

BH3-mimetics and BET-inhibitors elicit enhanced lethality in malignant glioma
por: Ishida, Chiaki Tsuge, et al.
Publicado: (2017)

Increased apoptotic sensitivity of glioblastoma enables therapeutic targeting by BH3-mimetics
por: Koessinger, Anna L., et al.
Publicado: (2022)

Navitoclax Most Promising BH3 Mimetic for Combination Therapy in Hodgkin Lymphoma
por: Langendonk, Myra, et al.
Publicado: (2022)

BH3-profiling identifies heterogeneous dependency on Bcl-2 family members in Multiple Myeloma and predicts sensitivity to BH3 mimetics
por: Touzeau, Cyrille, et al.
Publicado: (2015)

The BH3 mimetic drug ABT-737 induces apoptosis and acts synergistically with chemotherapeutic drugs in thyroid carcinoma cells
por: Broecker-Preuss, Martina, et al.
Publicado: (2016)

Treatment with a BH3 mimetic overcomes the resistance of latency III EBV (+) cells to p53-mediated apoptosis
por: Pujals, A, et al.
Publicado: (2011)

The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular carcinoma cells
por: Cheng, P, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_4fq96kc4l1git9thn76ltqbh0d